https://www.selleckchem.com/pr....oducts/doxycycline.h
5), 50% (0.5 ≤ PSA 1), 56% (1 ≤ PSA 2), 68% (2 ≤ PSA 5), and 94% (PSA ≥ 5), respectively. One hundred and two patients (62%) had changes in clinical management based on F-fluciclovine PET findings. Twelve of these patients (12%) had lesion localization on F-fluciclovine PET, despite negative conventional imaging. Treatment plans of 14 patients with negative F-fluciclovine PET were changed based on additional PET imaging with a different radiopharmaceutical. F-Fluciclovine PET/CT remains a useful diagnostic tool in the
Like
Comment
Share
